Merck, the sole supplier of measles vaccines in the U.S., said that the increase in demand was noticeable, but it was able to handle the uptick.
“Despite what we’ve seen as a huge uptick in the number of cases … the demand side of the equation hasn’t been outstripping our underlying capacity,” Mike Nally, head of Merck’s Global Human Health business and chief marketing officer, told Reuters.
As of April 26, the CDC had reported 704 cases of measles nationwide. Most cases were found in children who had not received the measles-mumps-rubella vaccine. The previous record was in 2014, when 667 measles cases were reported.
More articles on supply chain:
Free 1-day Prime shipping coming soon, Amazon says
A generic version of Narcan, a device for ADHD & more: 6 recent FDA approvals
How the US healthcare system can tackle its sustainability problem
